You are here

Company Discovers New Antibiotic Compound

The compound, AQP-182, has demonstrated bactericidal potency against multidrug-resistant Staphylococcus aureus (MDRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP), Clostridium difficile, and Enteroccocus faecalis—common causes of death in patients in hospital care units.

AQP-182 is one of the novel drug-like molecules identified by Aquapharm from its collection of more than 10,000 marine microorganisms. The company has identified 16 molecules of interest. AQP-182 is the most advanced of these molecules because of its activity against multi–drug-resistant gram-positive bacteria, with in vitro minimum inhibitory concentrations against MDRSA below 0.016 mcg/mL.

Aquapharm expects to initiate a phase I clinical study of AQP-182 in the second half of 2013.

For more information, visit the Aquapharm Biodiscovery Web site.

Recent Headlines

Safety concerns include liver injury and interactions with other drugs
No tobacco product is safe, says the lung heath group
Discovery seen as possibly leading to new anti-TB drugs
Study points to permanent hair dye and straighteners
How malaria parasites evade first-line drugs
A new way to fight staph infections
Score could help prevent misuse among cancer patients